Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors

$MRNS
$ARAV
$AMGN
$INO
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $MRNS alert in real time by email

BOSTON--()--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately. Mr. Shepard will also serve as a member of the Audit Committee. Following the appointment of Mr. Shepard, the Board is now composed of 11 directors, nine of whom are independent.

“We are excited to welcome Jay to Ironwood’s Board. Jay is a recognized leader within our industry with nearly three decades of expertise as an accomplished public company CEO and senior executive,” said Julie McHugh, chair of Ironwood’s Board. “We look forward to leveraging Jay’s deep expertise as we seek to further our mission to advance the treatment of GI diseases and redefine the standard of care for GI patients.”

Mr. Shepard commented, “I am delighted to join the Ironwood Board at such a dynamic time for the company and look forward to being a part of its future as the company continues executing on its GI-focused strategy.”

About Jay P. Shepard

Mr. Shepard was president and chief executive officer of Aravive, Inc. (formerly Versartis, Inc.), a clinical-stage oncology company, from May 2015 to January 2020, and served as a member of its board of directors from December 2013 to April 2020, including as chair of its board of directors from January 2020 to April 2020. From 2012 until May 2015, Mr. Shepard was an executive partner at Sofinnova Ventures, which he joined as an executive in residence in 2008. From 2010 to 2012, Mr. Shepard served as president and chief executive officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc. (acquired by Pfizer Inc.). From 2005 to 2007, Mr. Shepard served as president and chief executive officer and a member of the board of directors of Ilypsa, Inc. (acquired by Amgen Inc.), and then as interim chief executive officer of Relypsa, Inc. (Ilypsa’s spin-out company, which was acquired by Galencia Group) until 2008 and as a member of the Relypsa board of directors until 2010. Mr. Shepard currently serves on the board of directors of Inovio Pharmaceuticals, Inc., Esperion Therapeutics, Inc., and Craig Hospital and is chair of the board of directors for the Christopher & Dana Reeve Foundation. Mr. Shepard also served on the boards of directors of public companies, Marinus Pharmaceuticals, Inc., Durect Corporation and InterMune, Inc. (acquired by Roche Holding AG). Mr. Shepard holds a B.S. in Business Administration from the University of Arizona.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

Ironwood was founded in 1998 and is headquartered in Boston, Mass. For more information, please visit our website at www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

SOURCE: Ironwood Pharmaceuticals, Inc.

Get the next $MRNS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MRNS
$ARAV
$AMGN
$INO

CompanyDatePrice TargetRatingAnalyst
12/18/2024$4.00Neutral
Goldman
12/17/2024$8.00Overweight
Cantor Fitzgerald
12/10/2024$29.00Neutral
BofA Securities
12/10/2024$256.00Underperform
BofA Securities
11/15/2024$25.00Underperform
Wolfe Research
11/15/2024Peer Perform
Wolfe Research
11/14/2024$335.00Neutral
Citigroup
10/25/2024$30.00Neutral
Citigroup
More analyst ratings

$MRNS
$ARAV
$AMGN
$INO
Press Releases

Fastest customizable press release news feed in the world

See more
  • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program

    MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits (NIHB) Program for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.1 The Non-Insured Health Benefits (NIHB) Program provides eligible First Nations and Inuit

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

    WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer. "We are excited to welcome Noah Rosenberg to the Verrica team as our new Chief Medical Officer," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "As a highly accomplished drug development executive and physician, Noah's deep expertise will significantly help our efforts to establish YCANTH® as the new standard of care for the treatment of mo

    $ESPR
    $TVTX
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRNS
$ARAV
$AMGN
$INO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MRNS
$ARAV
$AMGN
$INO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MRNS
$ARAV
$AMGN
$INO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MRNS
$ARAV
$AMGN
$INO
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRNS
$ARAV
$AMGN
$INO
Leadership Updates

Live Leadership Updates

See more
  • Dexcom Appoints Jon Coleman as Chief Commercial Officer

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

    $DXCM
    $MASI
    $PFE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations
  • FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate

    Industry veteran in clinical development of oncology therapeutics, Dr. Jens Wurthner, PhD, joins as Chief Medical Officer Lead development candidate, FORX-428, a PARG inhibitor for solid tumors, maintains progress toward IND submission by mid-2025 FoRx Therapeutics AG, a Swiss-based company committed to discovering and developing innovative drugs targeting cancer-relevant DDR (DNA Damage Response) pathways, today announced that it has appointed Jens Würthner, MD PhD, as Chief Medical Officer. He is further strengthening FoRx Therapeutics' existing management team with CEO Tarig Bashir, CSO Frank Zenke, and Head of Chemistry Ulrich Lücking. Jens Würthner has 20+ years of clinical devel

    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    $AMGN
    $GSK
    $JNJ
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

$MRNS
$ARAV
$AMGN
$INO
Financials

Live finance-specific insights

See more
  • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

    CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

    Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules On track to begin rolling submission of BLA in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the yearAnnounced durability data from retrospective study showing that 50% of patients achieved a Complete Response in the second 12-month period (year 2) with 86

    $INO
    Medical/Dental Instruments
    Health Care

$MRNS
$ARAV
$AMGN
$INO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more